A large PET imaging study points to different dementia patterns
A large multisite study of older Americans with mild cognitive impairment or dementia found that Black and Hispanic patients were significantly less likely than other racial and ethnic groups to show Alzheimer’s-related amyloid pathology on brain scans. The work, reported in Alzheimer’s & Dementia and led by Vanderbilt Health researchers, adds weight to the idea that dementia symptoms do not always arise from the same underlying biology across populations.
The study included 5,757 Medicare recipients from around the United States, making it one of the largest positron emission tomography, or PET, imaging studies to examine ethnoracial differences in cognitive impairment. PET amyloid scans look for plaques associated with Alzheimer’s disease, which is estimated to account for 60% to 80% of dementia cases. But not every person with dementia symptoms has amyloid plaques, and the new findings suggest that this distinction matters for both care and access.
Why the result matters
The researchers said the results suggest that the large ethnoracial gaps seen in dementia may be explained in part by differences in the underlying causes of symptoms. That has direct implications for diagnosis, treatment, and research enrollment. If clinical pathways focus too narrowly on Alzheimer’s pathology, people whose symptoms stem from other causes may be overlooked.
The paper also highlights a practical concern. Among people who already have cognitive impairment, a normal amyloid PET result can reduce access to treatment options and to clinical trials that require evidence of Alzheimer’s pathology. The authors said their findings indicate that these disadvantages are likely to fall disproportionately on Black and Hispanic patients.
Socioeconomic context also showed up in the data
The study did not only examine race and ethnicity. It also looked at disadvantage at the area level and found another notable pattern: the odds of PET amyloid positivity were 40% greater in the most disadvantaged areas than in the most prosperous ones. That suggests social and environmental context may be shaping dementia risk in ways that are clinically meaningful.
Researchers described the work as an attempt to view cognitive impairment through a broader lens than is typical in imaging studies. Instead of assuming that dementia symptoms map cleanly onto a single disease process, the data support a more complex picture in which multiple forms of pathology, access barriers, and social conditions interact.
Implications for trials and treatment
The findings arrive at a time when Alzheimer’s diagnosis and treatment are becoming increasingly tied to biomarkers. That shift may improve precision for some patients, but it also raises the stakes for those whose symptoms are driven by other mechanisms. If biomarker-based eligibility becomes central to care, existing inequities could deepen unless research and clinical models account for diverse pathways into dementia.
The authors argued that the field urgently needs more work on causes of dementia beyond amyloid alone. The study does not dismiss Alzheimer’s disease as a major driver of cognitive decline. Instead, it argues that an exclusive fixation on Alzheimer’s pathology risks missing other contributors and may worsen already stark health differences.
A broader lesson for dementia research
One of the strongest messages from the study is that diversity in recruitment is not just a fairness issue. It changes the scientific picture. By assembling a large and geographically broad sample, the investigators were able to show patterns that may remain hidden in narrower cohorts.
For clinicians, the takeaway is caution against treating biomarker findings as the whole story. For researchers and health systems, the message is that dementia equity will require better understanding of how pathology, access, and social disadvantage intersect. The new study makes the case that improving dementia care means looking beyond a one-size-fits-all model of Alzheimer’s disease.
This article is based on reporting by Medical Xpress. Read the original article.
Originally published on medicalxpress.com
